Pfizer Eyes EU Pegfilgrastim Roll-Out By 1 April As US Launch Is Confirmed
No Update On Infringement Proceedings Over Protein Purification Patent
Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US by the end of the current quarter, a company spokesperson has informed Generics Bulletin, following a successful US launch.
